Journal Articles Conference Presentations Book Chapters Public Presentations

CpG Free Plasmids For Enhanced Duration & Reduced Toxicity Of Non-Viral Airway Gene Transfer.

Hyde SC

Download

European Society of Gene and Cell Therapy Conference, Bruges, 2008

The UK Cystic Fibrosis Gene Therapy Consortium is the combined research programme of the three UK gene therapy research groups that have performed cystic fibrosis gene transfer clinical studies. In support of our next phase of clinical studies we have undertaken an extensive pre-clinical research programme to identify a non-viral gene transfer formulation that:-

  1. Directs efficient pulmonary transgene expression after delivered by clinically relevant aerosolisation devices
  2. Is repeatedly administrable without loss of efficacy
  3. Is minimally inflammatory / toxic
  4. Is readily manufactured under cGMP.

During this evaluation we identified plasmid derived CG dinucleotides as the major source of host inflammation in response to non-viral gene delivery to the lung and thus developed a range of CG dinucleotide free expression vectors that are capable of sustained lung transgene expression in the absence of host inflammation.


 

Other Abstracts by these authors
Long-Term Stability of Aqueous pDNA/PEI Complexes.
Nunez-Alonso GA et al.
The American Society of Gene Therapy Annual Conference (2007) A clinical study to evaluate the safety and efficacy of pGM169/GL67A administered to the nose and lungs of individuals with cystic fibrosis.
Hyde SC et al.
The American Society of Gene and Cell Therapy Annual Conference (2010) Concentrated PEI Formulations Retain Biological Efficacy Following Long-Term Storage at 4°C.
Davies LA et al.
The American Society of Gene and Cell Therapy Annual Conference (2010) Aerosol Delivery of Concentrated pDNA/PEI Formulations to the Murine Lung.
Davies LA et al.
The American Society of Gene Therapy Annual Conference (2006) Repeat Administration of Polyethylenimine (PEI) Aerosols of Plasmid DNA to the Murine Lung is Associated with a Loss of Gene Transfer Efficiency.
Davies LA et al.
The American Society of Gene Therapy Annual Conference (2005) Knockdown of ENaCα, as a treatment for Cystic Fibrosis lung disease
Harding-Smith RE et al.
The American Society of Gene and Cell Therapy Annual Conference (2011)